Lincoln National Corp boosted its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 5.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 13,904 shares of the company’s stock after purchasing an additional 711 shares during the period. Lincoln National Corp’s holdings in Merck & were worth $891,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Perennial Advisors LLC grew its position in shares of Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the period. Stelac Advisory Services LLC acquired a new stake in shares of Merck & during the 2nd quarter valued at about $104,000. Vigilant Capital Management LLC grew its position in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the period. Cascade Investment Advisors Inc. grew its position in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the period. Finally, Solaris Asset Management LLC grew its position in shares of Merck & by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the period. 73.15% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently commented on the company. BMO Capital Markets restated an “outperform” rating and set a $73.00 target price (down from $74.00) on shares of Merck & in a research report on Monday, July 24th. BidaskClub cut Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Morgan Stanley cut Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 price objective on the stock. in a report on Monday, October 30th. Credit Suisse Group reiterated an “outperform” rating and issued a $74.00 price objective (down from $75.00) on shares of Merck & in a report on Tuesday, September 5th. Finally, UBS AG lowered their price objective on Merck & from $72.00 to $67.00 and set a “buy” rating on the stock in a report on Monday, October 30th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $67.07.
In related news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.25% of the company’s stock.
Merck & Company, Inc. (NYSE MRK) opened at $55.48 on Monday. The company has a market cap of $151,151.77, a price-to-earnings ratio of 14.26, a price-to-earnings-growth ratio of 2.39 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80.
Merck & (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.07 earnings per share. sell-side analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current year.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.